Jeffrey Wiezorek, SVP Clinical Development at Kite Pharma, Inc. (KITE), sold 800 shares at $68.92 ($60K) on 2017-03-01, disclosed to the SEC on 2017-03-02.
Open-market sale of $60k KITE by SVP Clinical Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $68.92 | 74 | $5K | 8.5% |
| 2 | $71.24 | 259 | $18K | 30.9% |
| 3 | $75.82 | 157 | $12K | 19.9% |
| 4 | $76.98 | 150 | $12K | 19.3% |
| 5 | $79.83 | 160 | $13K | 21.4% |
| Total | $74.72 avg | 800 |
| $60K |
| 100% |
| Filing → |
| KITE | SELL | 2017-02-06 | $77K | — | Filing → |
| KITE | SELL | 2017-01-10 | $75K | — | Filing → |
| KITE | SELL | 2016-12-22 | $36K | — | Filing → |